Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290671 | 0.79 | NPC1 (0.42) | CYP1A2CYP2A6ALDH1A1KDM4ENPC1 | |
| SCHEMBL21827151 | 0.78 | MAPT (0.41) | CHEK1CYP1A2ALDH1A1KDM4EPLAU | |
| SCHEMBL28290677 | 0.78 | NPC1 (0.41) | CYP1A2CYP2A6ALDH1A1KDM4ENPC1 | |
| SCHEMBL21845621 | 0.75 | USP30 (0.36) | CHEK1USP30 | |
| SCHEMBL1486301 | 0.74 | CHEK1 (0.50) | CHEK1CYP1A2CYP2A6PDPK1NOTUM | |
| SCHEMBL25242404 | 0.74 | PDPK1 (0.54) | CHEK1CYP1A2CYP2A6PDPK1NOTUM | |
| SCHEMBL13804176 | 0.74 | CYP1A2 (0.54) | CHEK1CYP1A2CYP2A6PDPK1NOTUM | |
| SCHEMBL3662977 | 0.74 | CHEK1 (0.49) | CHEK1CYP1A2CYP2A6PDPK1NOTUM | |
| SCHEMBL23741081 | 0.73 | USP30 (0.35) | MTORUSP30 | |
| Hydrochloric Acid SCHEMBL7398907 | 0.72 | CYP1A2 (0.52) | CHEK1CYP1A2CYP2A6PDPK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384793-A | A kind of sulfur alcohol compound and its application with HDAC6 inhibitory activity | 沈阳药科大学 | 2019-02-26 | — | — | CN | claimed |
| CN-108779104-A | Noval chemical compound for inhibiting Nampt and the composition comprising it | 延世大学校产学协力团 | 2018-11-09 | — | — | CN | claimed |
| CN-108368089-A | Novel Compounds | 特殊治疗有限公司 | 2018-08-03 | — | — | CN | claimed |
| CN-108341777-A | Compound of isobioquin group and its application | 四川科伦博泰生物医药股份有限公司 | 2018-07-31 | — | — | CN | claimed |
| CN-108017583-A | A kind of preparation method for winning U.S. | 徐州万邦金桥制药有限公司 | 2018-05-11 | — | — | CN | claimed |
| CN-107531589-A | Trka kinase inhibitors | GVK生物科技私人有限公司 | 2018-01-02 | — | — | CN | claimed |
| CN-103261167-B | 6 of replacement, 6-condenses nitrogen-containing heterocycle compound and uses thereof | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-04 | — | — | CN | claimed |
| CN-102076820-A | Liquid crystal compositions comprising compounds containing mesogen | TRANSITIONS OPTICAL INC | 2011-05-25 | — | — | CN | claimed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3860995-B1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-04-16 | — | — | EP | disclosed |
| CN-113574056-A | Isoquinoline compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113574056-A | Isoquinoline compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| CN-1117079-C | Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine | FIBRE GENE INC (US) | 2003-08-06 | — | — | CN | disclosed |
| CN-1117079-C | Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine | FIBRE GENE INC (US) | 2003-08-06 | — | — | CN | disclosed |
| EP-1295876-A1 | EPOXYCARBOXYLIC ACID AMIDES, AZIDES AND AMINO ALCOHOLS AND PROCESSES FOR PREPARATION OF ALPHA-KETO AMIDES BY USING THEM | SEIKAGAKU CORPORATION (JP) | 2003-03-26 | — | — | EP | disclosed |
| CN-1251525-A | Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as medicines for treating AIDS | BAYER AG (DE) | 2000-04-26 | — | — | CN | disclosed |
| CN-1218802-A | Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine | HOECHST MARION ROUSSEL CO LTD (DE) | 1999-06-09 | — | — | CN | disclosed |
| CN-1218802-A | Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine | HOECHST MARION ROUSSEL CO LTD (DE) | 1999-06-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | CHEK1 120/4885CYP1A2 2630/4885CYP2A6 3518/4885 |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | PGK1, PHKG1, NEK1 | CHEK1 120/4885CYP1A2 2630/4885CYP2A6 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.